PT Kalbe Farma Tbk · IDX:KLBF

PT Kalbe Farma Tbk — FY2024 Earnings Presentation

25 slides from PT Kalbe Farma Tbk's earnings presentation, February 2025

  1. Slide 1: Indicative 2024 Results & Outlook 2025

    Analyst Gathering Indicative 2024 Results & Outlook 2025 PT Kalbe Farma Tbk February 2025

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2024 unaudited results of the Company. The information con

  3. Slide 3: Table of Content

    Table of Content • Key Updates 04 • Key Business Strategies 08 • Financial Overview 19

  4. Slide 4: Key Updates

    y Key Updates

  5. Slide 5: More than Half a Century of Providing Wide-Range Healthcare Solutions

    More than Half a Century of Providing Wide-Range Healthcare Solutions Corporate Overview Market Capitalization Indonesian integrated healthcare company with regional footprint IDR 63.8 tn ($3.9 bn)* Onwards 1966 1991 free float Established, headquartered Listed in the The most integrated * healthcar

  6. Slide 6: Solid Foundation for Future Growth

    Solid Foundation for Future Growth Key Takeaways Strategic Partnerships and Investments FY24 Indicative FY24 Indicative 7.2% Net Sales growth 17.3% EPS growth Strengthening product portfolio through Strategic Partnership with Alliance Pharma Co.,Ltd. collaboration (Thailand) Key Updates Zerpidio and

  7. Slide 7: Driving Growth and Improving Healthcare Resilience through Innovation

    Driving Growth and Improving Healthcare Resilience through Innovation 2025 Key Strategies Investing for long term growth through innovation and collaboration Prescription Medical International Consumer Health Distribution Pharmaceuticals Devices Market & Nutritionals & Logistics Innovative Biologics

  8. Slide 8: Business Strategies

    y Business Strategies

  9. Slide 9: Driving Top Line Growth with Portfolio Strategy

    Driving Top Line Growth with Portfolio Strategy Prescription Pharmaceuticals Building Participation in Enhance Business Specialty Portfolio National Health Growth Steadily growing specialty Insurance by leveraging on category with Consistent growth strong commercial expanding innovative in E-Catalog

  10. Slide 10: Strategic Collaborations to Accelerate Growth

    Strategic Collaborations to Accelerate Growth Prescription Pharmaceuticals Sustaining Business Expansion through Strategic Partnerships Oncology Livzon Pharma Indonesia Shareholder Agreement Signing Jul 2024 To locally manufacture more advanced pharmaceuticals ingredients for the export market, by l

  11. Slide 11: Innovative Biologics Products

    Innovative Biologics Products Prescription Pharmaceuticals Approved Novel Biologics Strengthening Portfolio in Zerpidio (HLX10 – Serplulimab) Oncology • Approved in Dec 2023, commercialization in 2024 • Approved by local FDA in Thailand Serplulimab (Zerpidio 100 mg) Signing ceremony with Henlius for

  12. Slide 12: Rejuvenating Our Strong Brands to Win the Market

    Rejuvenating Our Strong Brands to Win the Market Consumer Health Expanding Driving Customer Base Product Innovation Leveraging solid customer Expanding to preventive base in OTC and health categories as future supplement with brand growth driver rejuvenation, strengthened branding and positioning

  13. Slide 13: Expanding into Preventive and Wellness Category

    Expanding into Preventive and Wellness Category Consumer Health Our Market Share Driving product innovation and new product launches in potential categories Strong Customer Loyalty 72% 46% new new Antacids Anti Diarrhea (Promag) (Entrostop) Extra Joss Mixagrip Promag Entrostop Komix Woods Procold Sa

  14. Slide 14: Navigating Market Turbulence to Drive Future Growth

    Navigating Market Turbulence to Drive Future Growth Nutritionals Extensive Strong Product Portfolio Complete product offering Product Innovation for all life stages with Expanding to affordable and strong functionality ready-to-drink categories

  15. Slide 15: Expanding to Affordable and Ready-to-Drink Products

    Expanding to Affordable and Ready-to-Drink Products Nutritionals Performs above the market New product launches Extensive Portfolio to Serve All Ages and Segments Expecting Mothers Lactating Mothers Kids Teens Adults Senior Clinical -3.1% Powdered Milk Market Nielsen 9M24 new new new new new 10 - 15

  16. Slide 16: Strong Distribution Network in Healthcare, Supported by Digital Expansion

    Strong Distribution Network in Healthcare, Supported by Digital Expansion Distribution and Logistics Strong Distribution Leveraging Optimizing Distribution Infrastructure digitalization Network Expansive multi-channels through EMOS and Optimized medical and network with coverage in 71 MOSTRANS B2B d

  17. Slide 17: Extensive Network in Pharmaceuticals Distribution

    Extensive Network in Pharmaceuticals Distribution Distribution & Logistics Major Third-Party Principals Prescription Pharmaceuticals Consumer +200K Outlets +200K 71 Branches Medical Instrument & Diagnostic Fine Chemical Raw Materials 3 3 Expanding to Cold-Chain Distribution Business Distribution Cen

  18. Slide 18: Moving Towards Local Manufacturing & Assembly

    Moving Towards Local Manufacturing & Assembly Medical Devices • Accelerate technology transfer to build local Surgical Suture, Mobile X-ray, and Dialyzer Facility manufacturing capabilities • Meet the local content requirements for JKN Program Consumables Surgical Suture Mobile X-ray Dialyzer Indige

  19. Slide 19: Financial Overview

    y Financial Overview

  20. Slide 20: Driving Top-line Growth Recovery

    Driving Top-line Growth Recovery Consolidated Operational Performance Net Sales 7.2% In IDR bn (unaudited) 32,649 30,449 12.3% 6.6% -2.1% 11.2% 9,807 10,901 8,222 9,235 8,372 8,198 4,049 4,315 Prescription Consumer Health Nutritionals Distribution & Logistics Total Consolidated Pharmaceuticals Net S

  21. Slide 21: Sustained Margin Improvement Trend

    Sustained Margin Improvement Trend Consolidated Operational Performance Gross Profit Operating Expenses to Net Sales Net Income 10.0% 17.1% 26.7% 27.1% 9.1% 9.9% 38.8% 39.8% 1.1% 1.4% 4.9% 4.7% R&D Expenses G&A Expenses Selling Expenses 12,993 20.7% 21.0% 3,240 11,815 2,767 Dec 23 Dec 24 Dec 23 Dec

  22. Slide 22: Securing Product Availability by Managing Inventory

    Securing Product Availability by Managing Inventory Working Capital Management 180 162 160 153 Managing Net Operating Cycle 137 140 129 • Inventory level has continued to normalize 147 120 • Improve working capital by building strong 120 131 relationships with clients and suppliers 122 118 100 • Con

  23. Slide 23: Healthy Cash Balance to Support Operation and Business Expansion

    Healthy Cash Balance to Support Operation and Business Expansion Capital Allocation Total Debt & Gearing Ratio Cash & Cash Equivalent 1,200 5.8% 5.1% 7.0% 6,216 7.0% 5,590 1,000 6.0% 5,208 6.0% 4,716 5.0% 4,050 4,329 800 3,950 2.6% 2.5% 5.0% 4.0% 3,232 600 2,833 2,656 1,067 1,116 1.6%4.0% 3.0% 400 2

  24. Slide 24: Focusing on Top and Bottom-Line Improvement

    Focusing on Top and Bottom-Line Improvement Outlook 2025 Growing above the market & Consistently optimizing commercializing new Improving profitability shareholders' return innovative products YoY Sales Growth EPS Growth Dividend Payout 8 to 10% 8 to 10% Ratio 45 to 55% FY24 Indicative : 7.2% FY24 I

  25. Slide 25: For further information: PT Kalbe Farma Tbk

    For further information : PT Kalbe Farma Tbk | Jalan Let. Jend. Suprapto Kav. 4 | Jakarta 10510, Indonesia Tel. : 62-21-42873888 | Fax. : 62-21-42873678 Email : [email protected] [email protected]

PT Kalbe Farma — FY2024 Earnings Presentation on 6ix